Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients.
about
Practical management of classical myeloproliferative disorder patients: a clinician's guideThalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies.Palliative splenectomy in myelofibrosis with myeloid metaplasia.Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosisThe optimal management of polycythaemia vera.A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.Hepatic manifestations in hematological disorders.Osteomyelosclerosis with thalassemia trait: report of a rare association, study of platelet function tests and review of literature.Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases.Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the Literature.Pacritinib: a new agent for the management of myelofibrosis?Management of Hematologic Malignancies: Special Considerations in Pregnant Women.The role of the extracellular matrix in primary myelofibrosis.Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia.Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study.Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis.Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.Current perspective in agnogenic myeloid metaplasia.Agnogenic myeloid metaplasia.Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study.Factors affecting prognosis in myelofibrosis(18)F-FDG PET/CT for Detection of Metachronous Hodgkin's Disease in Patients with Myelofibrosis.Thalidomide in agnogenic and secondary myelofibrosis.Thalidomide treatment in myelofibrosis with myeloid metaplasia.Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients.Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients.Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents.Prognostication in primary myelofibrosis.Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact.The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.
P2860
Q28200207-B1BC3165-B5FF-4F79-ACC2-809D8AE490D4Q30773458-D3FFC620-651D-4ADD-8C7B-218EDD2CC80DQ33328618-B002A078-6A0E-4026-9F23-3BA85219DAADQ33339654-D30308C3-54AA-4E8D-8A6B-C5A9C24CD8BCQ33406990-420F19CF-4853-454A-A7FC-AD9370A3C248Q33433006-472F68FB-AB43-419E-AFF9-1E22626AAA33Q33753094-3CC86583-072A-4B2A-B683-7F26812FFE0CQ34247430-41D97D71-7B1B-4B6C-AB81-575104B747B3Q34527669-D467813E-9857-4AC2-913A-4CD5A27FBD65Q36362041-9871F291-DA03-4496-B552-D889940C2237Q36765838-07EFDEC6-65E2-42E2-8F12-AA3C35B04FAFQ37212358-41486E9C-1309-489E-A8E7-7366CEF4EF78Q37250357-2726D14E-6C06-4D14-999E-D4DD94B6F811Q38041128-95796E61-F8BD-4C64-86AD-1ABF2AE2EB8AQ38590232-A47D1E37-2633-4F7D-B9B8-27A257DDAAADQ38594889-AE3F37BA-3E84-4446-B085-D168AD2D396EQ39117766-DF7CAF54-E025-4AEE-8813-80C5D3FE1D3FQ39443425-F2A44760-4A1B-4B63-83CA-7145493BB206Q40587986-39DBFE84-D16C-4170-95E6-913EEEA94F20Q40679370-70296B3C-50FD-4B7A-AE41-5D6EA7E3046DQ41253030-9FF9BB26-1CF2-4B56-BE8F-BBA3248F2CC1Q41253215-E4A3801B-20F2-4B28-898C-D9ED1D1E50B0Q41421730-F656069B-DD9C-495E-B1B6-0BA8AEA85098Q41560568-D1DDBF56-7EF7-4986-B3E4-81D49F35BEA0Q41966332-D5E347C0-0136-4C71-B3B9-73FE94D765EDQ42131355-4AE3B0A9-9A8A-4490-B619-3831B262AD75Q43795704-9143AFA8-DD5B-42C4-A632-07751A6743D0Q43969504-337D90DE-1B4C-40A1-8D74-90E91F3F0780Q44300500-38B82790-8040-437F-AC89-72A0B23A3DC6Q44509200-2308CA90-732A-40BA-845F-9EBF8CA6AFA4Q44529465-375966A9-50AB-4F77-9F66-85FC4E79C225Q44731549-39223CF3-85D5-46CC-8A7F-4C92572DE9CEQ51008176-25A7399C-B498-4BD7-A32D-D966DD4CB336Q53111428-382BEF0A-EDD1-4FFE-B01A-B84D9CF9AF49Q53979216-EC6A7312-275F-40C6-8D84-E92C21FD046A
P2860
Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients.
description
1990 nî lūn-bûn
@nan
1990 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Myelofibrosis with myeloid met ...... l in a series of 133 patients.
@ast
Myelofibrosis with myeloid met ...... l in a series of 133 patients.
@en
type
label
Myelofibrosis with myeloid met ...... l in a series of 133 patients.
@ast
Myelofibrosis with myeloid met ...... l in a series of 133 patients.
@en
prefLabel
Myelofibrosis with myeloid met ...... l in a series of 133 patients.
@ast
Myelofibrosis with myeloid met ...... l in a series of 133 patients.
@en
P2093
P2860
P1476
Myelofibrosis with myeloid met ...... l in a series of 133 patients.
@en
P2093
Aloe Spiriti MA
Castelli U
Latagliata R
Vianelli N
P2860
P356
10.1111/J.1365-2141.1990.TB02609.X
P407
P577
1990-05-01T00:00:00Z